Modus Therapeutics Holding AB (MODTX) - Total Liabilities
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has total liabilities worth Skr3.62 Million SEK (≈ $389.03K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Modus Therapeutics Holding AB - Total Liabilities Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's total liabilities have evolved over time, based on quarterly financial data. See Modus Therapeutics Holding AB short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Modus Therapeutics Holding AB Competitors by Total Liabilities
The table below lists competitors of Modus Therapeutics Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nrgene Technologies Ltd
TA:NRGN
|
Israel | ILA5.12 Million |
|
Iron Road Ltd
AU:IRD
|
Australia | AU$503.59K |
|
Imunon Inc
NASDAQ:IMNN
|
USA | $4.66 Million |
|
Equity Story Group Ltd
AU:EQS
|
Australia | AU$2.69 Million |
|
Orient Press Limited
NSE:ORIENTLTD
|
India | Rs951.97 Million |
|
Dnonce Tech Bhd
KLSE:7114
|
Malaysia | RM125.54 Million |
|
Patkol Public Company Limited
BK:PK
|
Thailand | ฿1.48 Billion |
|
Dynasty Gold Corp
V:DYG
|
Canada | CA$542.41K |
Liability Composition Analysis (2018–2025)
This chart breaks down Modus Therapeutics Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Modus Therapeutics Holding AB (MODTX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Modus Therapeutics Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual total liabilities of Modus Therapeutics Holding AB from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr3.62 Million ≈ $389.03K |
+31.60% |
| 2024-12-31 | Skr2.75 Million ≈ $295.62K |
+16.45% |
| 2023-12-31 | Skr2.36 Million ≈ $253.87K |
-82.97% |
| 2022-12-31 | Skr13.86 Million ≈ $1.49 Million |
+153.96% |
| 2021-12-31 | Skr5.46 Million ≈ $587.15K |
+1000.00% |
| 2020-12-31 | Skr496.00K ≈ $53.38K |
-89.53% |
| 2019-12-31 | Skr4.74 Million ≈ $509.78K |
-79.45% |
| 2018-12-31 | Skr23.05 Million ≈ $2.48 Million |
-- |
About Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more